Infliximab in the management of severe pemphigus vulgaris [12]

British Journal of Dermatology

Volumn 153, Issue 1, 2005, Pages 222-223

  Pardo, J ^a   Mercader, P ^a   Mahiques, L ^a   Sanchez Carazo J L ^a   Oliver, V ^a   Fortea, J M ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THALIDOMIDE;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; LETTER; MALE; PATIENT CARE; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; MALE; MIDDLE AGED; PEMPHIGUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22944467520     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06672.x     Document Type: Letter

References (10)

1. Feliciani C, Toto P, Amerio P et al. In vitro and in vivo expression of interleukin-1a and tumor necrosis factor-a mRNA in pemphigus, vulgaris: interleukin-1a and tumor necrosis factor-a are involved in acantholysis. J Invest Dermatol 2000; 114:71-7.
2. López-Robles E, Avalos Diaz E, Vega-Memije E et al. TNFa and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001; 40:185-8.
3. Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res 2003; 295 (Suppl. 1):S2-11.
4. Ohyama M, Amagai M, Tsunoda K et al. Immunologic and histopathologic characterization of an active disease mouse model for pemphigus vulgaris. J Invest Dermatol 2002; 118:199-204.
5. Feliciani C, Toto P, Wang B et al. Urokinase plasminogen activator mRNA is induced by IL-1a and TNFa in in vitro acantholysis. Exp Dermatol 2003; 12:466-71.
6. Feliciani C, Toto P, Amerio P. In vitro C3 mRNA expression in pemphigus vulgaris: complement activation is increased by IL-1α and TNF-α. J Cutan Medical Surg 1999; 3:140-4.
7. Williams JD, Griffiths CE. Cytokine blocking agents in dermatology. Clin Exp Dermatol 2002; 27:585-90.
8. Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rifuximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140:91-6.
9. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003; 28:366-8.
10. Schuh T, Besch R, Braungart E et al. Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. Biol Chem 2003; 384:311-15.